Engineering a Potential Cure For HIV: The Next Frontier in Biotech Investment

The Devastating Impact of HIV

Millions of people worldwide are living with HIV, a chronic, life-altering virus that attacks the body's immune system. While significant advancements in treatment have allowed individuals with HIV to live longer lives, the virus can still have a profound impact on a person's physical and mental well-being.

Here are some of the challenges faced by individuals living with HIV:

Weakened Immune System: HIV weakens the immune system, making individuals more susceptible to opportunistic infections and certain cancers.

Chronic Illness Management: Living with HIV often requires lifelong adherence to complex medication regimens, which can come with side effects and can be emotionally and physically demanding.

Stigma and Discrimination: Despite significant progress in education and awareness, stigma and discrimination against people living with HIV persist, creating additional emotional and social burdens.

948a7129-1b43-4dbf-ba8b-31884c8c6b3e
43db60c5-011b-42b2-9396-5b34e4ea18c8

Invest with Us to Transform HIV Treatment

Get in touch with Barry Wells, MD

f7001b25-754d-4585-9f83-43de58c69b18
318c6b76-fd5e-4ee6-adeb-b611115b236e

The Need for a
Functional Cure

Despite significant progress, HIV remains a global health crisis. Current treatments, while effective, are not accessible to everyone, and long-term use carries costs and challenges. A functional cure could revolutionize HIV care, potentially offering a one-time solution that allows individuals to manage the virus without the need for daily medication.

Addimmune's Approach

Addimmune, is dedicated to developing a functional cure for human immunodeficiency virus (HIV). Addimmune is pioneering AGT103-T, a potentially groundbreaking first-in-class functional cure, and maintains a robust pipeline of diverse gene therapy strategies designed to combat the complexities of the HIV genome. Based in Rockville, MD, Addimmune's team of passionate scientists, physicians, and experts strive to develop a safe and effective approach that modifies a patient's immune cells, enabling them to recognize and eliminate HIV-infected cells, ultimately leading to a cure.

Our Competitive Advantage

2c4f1c81-5044-4094-b502-06f2e1574be3

Proven Safety & Unexpected Positive Signals

Addimmune, is dedicated to developing a functional cure for human immunodeficiency virus (HIV). Addimmune is pioneering AGT103-T, a potentially groundbreaking first-in-class functional cure, and maintains a robust pipeline of diverse gene therapy strategies designed to combat the complexities of the HIV genome. Based in Rockville, MD, Addimmune's team of passionate scientists, physicians, and experts strive to develop a safe and effective approach that modifies a patient's immune cells, enabling them to recognize and eliminate HIV-infected cells, ultimately leading to a cure.

Analytical Treatment Interruption & Unique Response

We took the bold step of investigating our therapy's impact via an analytical treatment interruption (ATI). To our surprise, we saw a unique immune response across all six participants – increased CD8 cell count after viral rebound and stable CD4 cell count. This suggests AGT103-T may help the immune system build a defense against HIV.

Second ATI & Potential for Improvement

Intrigued by these results, we conducted a second ATI with four participants. We observed consistent immune responses, but even more compellingly, significantly reduced peak viremia and notably lower viral set points. This indicates the immune system may be 'learning' with repeated exposure, potentially leading to even better control with subsequent treatments.

These early clinical results suggest clear competitive advantages:

Safety First: A well-tolerated therapy is crucial for wider adoption.

Unique Responses: We see immune system effects not observed with other HIV gene therapies.

Adaptive Potential: Our data hints at improving viral control over time, positioning AGT103-T as a truly transformative solution.

200db174-a2be-4934-acfd-5e6973ec00ec
3f0e81cd-6588-496c-ad8e-25f5edcdcd95

Experienced, Empathetic & Success Focused

Our leadership team at American Gene Technologies and our HIV division Addimmune, combines decades of experience in immunology, HIV clinical care, and launching groundbreaking medical ventures and businesses. This unique blend of expertise drives our patient-focused approach, guiding us from scientific strategy to clinical design. We've achieved encouraging early clinical results and are strategically positioned for the complex path toward bringing a functional HIV cure to market, with the ultimate goal of creating a future where HIV is a manageable condition, not a life-defining one.

Jeff Galvin

CEO of American Gene Technologies™ and its HIV-focused division, Addimmune ™

Barry Wells, MD

Head of Business Development

Events

UPCOMING

Date Title
04.17.24     CMO360
05.07.24ASGCT: American Society of Gene & Cell Therapy Conference
05.28.24ISCT: International Society for Cell & Gene Therapy Presentation
06.03.24BIO International
06.22.24IAS: International AIDS Socitety
10.22.24ESGCT: European Society of Gene & Cell Therapy

PAST

Date Title
09.26.23     Cantor Fitzgerald Global Healthcare Conference
10.12.23ROTH MKM 2023 Healthcare Opportunities Conference
01.08.24J.P. Morgan Healthcare Conference
03.03.24CROI: Conference on Retroviruses & Opportunistic Infections

Contact Us for Investment Opportunities

Reach out to Barry Wells, MD

Accelerating Towards a Functional Cure: Our Development Timeline

We took the bold step of investigating our therapy's impact via an analytical treatment interruption (ATI). To our surprise, we saw a unique immune response across all six participants – increased CD8 cell count after viral rebound and stable CD4 cell count. This suggests AGT103-T may help the immune system build a defense against HIV.

Here is what it means:

Preclinical Success: Robust preclinical data demonstrated safety and potential efficacy

Phase 1a Complete: Initial safety and feasibility established, unexpected positive signals observed.

Analytical Treatment Interruptions: Unique immune responses observed with ATIs.

Treatment Approach
  Early
Discovery
Preclinical PH Ia Ph Ib Ph II
AGT103-T
AGT103-T Vaccine
AGT103-T+
AGT103-T+
AGT103-T+
Diagnostic
  Discovery Analytical
Validation
Clinical
Validation
Commercial
Launch
AGT103-T SEQ